cannabidiol extract
Phase 3Small molecule
cannabidiol extract is one of 68 small molecule programs targeting Osteoarthritis. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1cannabidiol extract
MMilton S. Hershey Medical Center
Phase 3
Epidiolex
Jazz PharmaceuticalsPreclinical
Ilaris
NovartisPreclinical
Toradol
RochePreclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Bayer Aspirin
BayerPreclinical
Glucophage
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Paracetamol
GSKPreclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for cannabidiol extract. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMilton S. Hershey Medical Center